Delivery Order SPE2DB22D2007-SPE2DB25FJ5KP
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Benlysta 400 mg vials, with a ceiling value of $13,678.56 and firm fixed pricing. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 15, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 8, 2025, for the supply of Benlysta 400 mg vials under a firm fixed price contract valued at $3,944.43, with a completion date of September 29, 2025. The contract was competitively awarded without set-aside provisions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is funded through the Defense Logistics Agency's Medical Supply Chain, which procures pharmaceutical and medical...
- The Defense Logistics Agency awarded a delivery order valued at $15,777.72 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials. This contract, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, is a firm fixed-price delivery order with no set-aside designation. The award was made competitively and represents a specific fulfillment requirement under AmerisourceBergen's larger federal contract vehicle supporting military healthcare procurement....
- The Defense Logistics Agency awarded a $18,147.78 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 4, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a single transaction under...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $7,888.86 in Benlysta 400 mg vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply relationship with the Defense Logistics Agency. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200MG VL 1S pharmaceutical product on September 13, 2025. This firm fixed price delivery order, valued at $3,082.67, represents a competitive award with no set-aside designation and is scheduled for completion by September 13, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,165.34 on August 13, 2025, for the supply of Benlysta 200 mg/mL auto-injectors under a firm fixed price contract. This non-set-aside competitive award supports the Defense Logistics Agency's Medical Supply Chain operations, with a performance location in Conshohocken, PA and an ultimate completion date of September 4, 2025. The delivery order represents a child contract action...
- The Defense Logistics Agency awarded a delivery order valued at $15,777.72 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for Benlysta 200 mg/ml auto-injector pharmaceutical supplies. This $6,165.34 firm fixed price delivery order is scheduled for completion by September 3, 2025, and represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,330.68 for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is located in Conshohocken,...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5KPDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Benlysta 400 mg vials, with a contract ceiling value of $15,777.72. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025. The contract was awarded on a competitive basis without any set-aside designation. AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply arrangement. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a broad portfolio of medications, vaccines, and medical supplies to support military and veteran healthcare systems. The Benlysta vials—a biologic medication used to treat systemic lupus erythematosus—represent part of the company's specialized pharmaceutical offerings across multiple therapeutic domains delivered through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.8k | 9/26/25 |